CAMBRIDGE, Mass.--(BUSINESS WIRE)--Casebia Therapeutics, an innovative gene editing company discovering and developing curative treatments for genetic diseases, today announced it has appointed Adel Nada, M.D., as the company’s first Chief Medical Officer.
Dr. Nada brings more than 15 years of leadership in clinical research, drug discovery and clinical development to Casebia, which is pursuing life-changing therapeutics to cure patients suffering from genetic diseases of the eye, ear and blood, as well as autoimmune, metabolic and cardiovascular conditions.
“Adel brings an unparalleled level of experience in gene editing and cell therapies, as well as broad experience in hematology, drug discovery and translational drug development,” said James Burns, Ph.D., President and CEO of Casebia. “His track record of accomplishment at many leading biopharmaceutical companies speaks to his unique abilities in advancing drug candidates in a broad range of therapeutic modalities.”
At Casebia, Dr. Nada will serve as Chief Medical Officer and head of translational science and clinical development. He will lead development activities from pre-clinical development through clinical development efforts across Casebia’s therapeutic areas and platforms. In addition, he will play a pivotal role in advancing the company’s overall R&D strategy. Dr. Nada will serve on Casebia’s Executive Leadership Team.
Most recently, Dr. Nada served as vice president and head of clinical development at Intellia Therapeutics. Prior to his time at Intellia, Dr. Nada was vice president of immunotherapy at Caladrius Biosciences of New York (previously known at NeoStem). Earlier, he served as senior medical director of cardiovascular cellular therapies at Baxter Healthcare Corp. He also held a variety of positions of increasing responsibility at Abbott Laboratories, including serving as medical director of several clinical development teams.
Dr. Nada earned his medical degree at Alexandria University in Egypt, and conducted his medical internship and residency at John H. Stronger Hospital in Chicago. He separately earned a master’s degree in clinical research from Rush University, and his designation as a Certified Physician Investigator from the Academy of Pharmaceutical Physicians and Investigators. He has received awards and recognition from several of his previous companies, and Dr. Nada serves on several industry organizations including acting as the white papers executive editor for the Alliance for Regenerative Medicine (ARM) Science and Technology Committee.
About Casebia Therapeutics
Casebia Therapeutics is a novel
joint venture between Bayer and CRISPR Therapeutics, formed in 2016 to
advance CRISPR/Cas9 gene-editing therapeutics to discover and develop
curative treatments for patients suffering from genetic diseases of the
eye, ear and blood, as well as autoimmune, metabolic and cardiovascular
conditions. The Casebia technology platform is moving genetic medicine
forward by enabling new genetic engineering tools and revolutionary
delivery methods for gene editing that target treatments precisely to
specific areas of the body affected by disease. Casebia’s headquarters
are in Cambridge, MA, with a research center in San Francisco, CA. For
more information, please visit www.casebia.com
or follow us at @casebiatx.
